RITA Medical Systems Announces Market Release of Habib 4X Laparoscopic(TM)
30 Noviembre 2006 - 5:30AM
PR Newswire (US)
Newly Introduced Laparoscopic Surgical Device Designed to Reduce
Blood Loss, Decrease Operating Times, Coagulate Highly Vascularized
Tissue FREMONT, Calif., Nov. 30 /PRNewswire-FirstCall/ -- RITA
Medical Systems, Inc. (NASDAQ:RITA), a publicly-traded medical
device company focused solely on cancer therapies, today announced
the start of market release shipments of the Habib 4X
Laparoscopic(TM) resection device. The Habib 4X Laparoscopic uses
radiofrequency (RF) energy to coagulate tissue and is designed to
assist surgeons to reduce blood loss and decrease operating times
during laparoscopic resection of vascularized tissue. Alan J.
Koffron, MD, Assistant Professor of Surgery, Division of Organ
Transplantation, Northwestern Memorial Hospital in Chicago,
Illinois stated, "Controlled transection of the liver parenchyma
(and therefore reduction of blood loss) during laparoscopic liver
resection is critical to patient safety and can often be the
determining factor when deciding to perform either traditional open
surgery or minimally invasive procedures. My early clinical
experience with the device has been striking in regard to liver
transection, and I believe that its use will make it possible for
me to offer the benefits of minimally invasive surgery to more of
my patients." The Habib 4X Laparoscopic resection device coagulates
a surgical resection plane to facilitate a fast dissection with
limited blood loss. The Company believes this technology will be
utilized in a variety of cancer surgeries, including liver and
kidney, as it is designed to minimize blood loss and the need for
blood transfusion during or after resection. The Habib 4X
Laparoscopic resection device is designed to work on the current
RITA RFA platform of 1500X(TM) Generators. Joseph DeVivo, President
and CEO of RITA commented, "We believe the laparoscopic Habib has
the opportunity to become a useful surgical tool across a broad
range of procedures. The early clinical use of the device, while
focused on liver resection, is only the beginning of what we
believe will be broad-based clinical application by laparoscopic
surgeons." Mr. DeVivo concluded, "We are grateful to
thought-leaders like Dr. Koffron and his team who were instrumental
in defining the best practices for early use of the device. We
believe that these talented clinicians will continue to explore
applications of laparoscopic resection and the benefits of rapid
tissue coagulation in other organs and other procedures." The Habib
4X Laparoscopic is CE marked for distribution in Europe, and was
cleared for use to assist in coagulation of tissue during
intraoperative and laparoscopic surgical procedures by the U.S.
Food and Drug Administration (FDA) in October of 2006. About RITA
Medical Systems, Inc. RITA Medical Systems develops, manufactures
and markets innovative products for cancer patients including
radiofrequency ablation (RFA) systems and embolization products for
treating cancerous tumors as well as percutaneous vascular and
spinal access systems. The Company's oncology product lines include
implantable ports, some of which feature its proprietary Vortex(R)
technology; tunneled central venous catheters; and safety infusion
sets and peripherally inserted central catheters used primarily in
cancer treatment protocols. The radiofrequency product line also
includes the HABIB 4X resection device which coagulates a "surgical
resection plane" and is designed to facilitate a fast dissection in
order to minimize blood loss and blood transfusion during surgery.
The proprietary RITA RFA system uses radiofrequency energy to heat
tissue to a high enough temperature to ablate it or cause cell
death. In March 2000, RITA became the first RFA company to receive
specific FDA clearance for unresectable liver lesions in addition
to its previous general FDA clearance for the ablation of soft
tissue. In October 2002, RITA again became the first company to
receive specific FDA clearance, this time for the palliation of
pain associated with metastatic lesions involving bone. The Company
also distributes LC Bead(TM) embolic microspheres in the United
States. The LC Bead microspheres are injected into selected vessels
to block the blood flow feeding a tumor, causing it to shrink over
time, and are often used in combination with RFA. The RITA Medical
Systems website is at http://www.ritamedical.com/. The statements
in this news release related to the introduction of the HABIB 4X
Laparoscopic resection device; the use of the laparoscopic version
of the HABIB 4X resection device in surgeries involving organs
other than the liver; the performance of the HABIB 4X Laparoscopic
resection device; and physician adoption of the HABIB 4X
Laparoscopic Resection device are forward- looking statements
involving risks and uncertainties that could cause actual results
to differ materially from those in such forward-looking statements.
Such risks and uncertainties include but are not limited to: the
risk of product defects, recalls or failures; potential product
delays caused by unforeseen manufacturing challenges; reliance on a
small number of suppliers for components of the HABIB 4X
Laparoscopic resection device; compliance with FDA regulations; and
physician training efforts. Information regarding these risks is
included in the Company's filings with the Securities and Exchange
Commission. DATASOURCE: RITA Medical Systems, Inc. CONTACT:
investors, Doug Sherk, , or Jenifer Kirtland, , both of EVC Group,
+1-415-896-6820, for RITA; or Stephen Pedroff, VP Marketing
Communications of RITA Medical Systems, Inc., +1-510-771-0400; or
media, Steve DiMattia of EVC Group, +1-646-201-5445, or , for RITA
Web site: http://www.ritamedical.com/
Copyright
Rita Medical (NASDAQ:RITA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Rita Medical (NASDAQ:RITA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Rita Medical Systems (NASDAQ): 0 recent articles
Más de Rita Medical Systems (MM) Artículos de Noticias